Lupin enters CDMO business, names Abdelaziz Toumi as CEO of new subsidiary

Drug maker Lupin said it has entered contract development and manufacturing organisation (CDMO) business, with newly formed subsidiary, Lupin Manufacturing Solutions (LMS).

The company on Monday named Abdelaziz Toumi (Abdel) as the chief executive officer of LMS.

LMS will engage in the development, manufacture and sale of active pharmaceutical ingredients and is starting to build its CDMO.


Lupin said Abdel with over two decades of experience in the biotech, pharma and CDMO sectors, spanning Europe, North America and Asia, has held leadership positions at Bayer, Merck, Catalent, Lonza, and KBI Biopharma, where he was responsible for driving growth, innovation and operational excellence.

Abdel will be based in Switzerland and will spend considerable time in India.

“We are delighted to welcome Abdel to our team. He brings a wealth of knowledge and experience in the API CDMO space and will be instrumental in establishing LMS as a trusted and preferred partner for our global customers,” said Lupin’s managing director, Nilesh Gupta.